Robert Wood, MD: Impact of Omalizumab Approval on Management of Pediatric Food Allergy

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

Related Keywords

United States ,American ,America , ,Novartis Pharmaceuticals Corporation ,Novartis ,American Academy Of Allergy ,Genentech ,National Institutes Of Health ,Office Of The Commissioner ,Drug Administration ,Division Of Pulmonology ,Kelly Stone ,Critical Care ,Drug Evaluation ,Biologics License Application ,National Institutes ,Immunology Annual ,Priority Review ,Adults With Food Allergies Based ,Positive National Institutes ,Health Phase ,Press Releases ,Food Allergy ,Pediatric Food Allergy ,Omalizumab ,Xolair ,Xolair Approval ,Outmatch Trial ,Food Allergy Treatments ,Omalizumab Xolair ,